Tourette Syndrome Treatment Market Report 2026

The tourette syndrome treatment market size has grown strongly in recent years. It will grow from $2.48 billion in 2025 to $2.63 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to availability of established antipsychotic medications, increased clinical acceptance of behavioral therapies, expansion of specialty neurology clinics, growing diagnosis of tourette syndrome, improved access to treatment services.

The tourette syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $3.38 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing investment in next-generation drug development, rising focus on personalized medicine approaches, expansion of teletherapy and remote care models, growing demand for safer long-term treatments, increasing clinical trial activity. Major trends in the forecast period include increasing use of targeted pharmacological therapies, growing adoption of comprehensive behavioral intervention for tics, expansion of combination therapy approaches, rising development of novel drug classes, improved patient monitoring and follow-up.

The rising healthcare expenditure is expected to drive the growth of the tourette syndrome treatment market in the coming years. Healthcare expenditure refers to the total spending on healthcare goods and services, including medical treatments, medications, hospitalizations, and preventive care over a specific period, reflecting the overall cost of healthcare provision for a population. Healthcare spending is increasing due to factors such as the rising cost of advanced medical technologies, aging populations, and the prevalence of chronic diseases. In the context of tourette syndrome treatment, healthcare expenditure is used to develop advanced diagnostic tools, medications, and behavioral therapies, as well as to support ongoing research, patient education, and access to specialized care services. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, marking a significant acceleration compared with the 0.9% growth observed in 2022. Therefore, increasing healthcare expenditure is supporting the growth of the tourette syndrome treatment market.

Leading companies in the tourette syndrome treatment market are focusing on targeted dopamine 1 (D1) receptor antagonists to gain a competitive edge. D1 receptor antagonists are drugs that block dopamine D1 receptors in the brain, reducing dopamine activity to help manage neurological or psychiatric conditions. For example, in March 2023, Emalex Biosciences, a US-based biopharmaceutical company, launched a Phase 3 study of ecopipam, a first-in-class small-molecule drug that selectively blocks D1 receptors and is not classified as an antipsychotic. Ecopipam demonstrated durable reductions in motor and vocal tics over 12 months with minimal metabolic side effects and no significant weight gain compared to traditional D2-targeting antipsychotics. This trend toward more precise and better-tolerated drug mechanisms enhances the likelihood of regulatory approval and broader adoption, although long-term safety and real-world effectiveness remain to be fully evaluated.

In February 2025, Relmada Therapeutics Inc., a US-based biotechnology company, acquired Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB for an undisclosed amount. The acquisition aligns with Relmada’s mission to address unmet needs in treating central nervous system (CNS) disorders. Sepranolone showed promising results in Phase 2a trials, with significant reductions in tics, improvements in quality of life, and strong safety data. Asarina Pharma AB is a Sweden-based provider of tourette syndrome treatments.

Major companies operating in the tourette syndrome treatment market are AbbVie Inc., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals, Neurocrine Biosciences, Sunovion Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., SciSparc Ltd., Emalex Biosciences Inc., Relmada Therapeutics Inc., Reviva Pharmaceuticals Inc., Catalyst Pharmaceuticals Inc., Psyadon Pharmaceuticals Inc., Sage Therapeutics Inc., Ipsen Pharma, Aptinyx Inc., Zynerba Pharma Inc., Teva Pharmaceutical Industries Ltd., H Lundbeck AS, NeuroSigma Inc.

North America was the largest region in the tourette syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tourette syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tourette syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tourette syndrome treatment market by increasing costs of imported active pharmaceutical ingredients, specialized drug formulations, neuromodulation devices, and digital therapy platforms. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to reliance on cross-border drug supply chains, while emerging markets face higher treatment costs. These tariffs are contributing to elevated drug prices and delayed market entry of new therapies. At the same time, they are encouraging domestic drug manufacturing, local formulation development, and regional clinical research to reduce long-term dependency on imports.

The tourette syndrome treatment market research report is one of a series of new reports that provides tourette syndrome treatment market statistics, including tourette syndrome treatment industry global market size, regional shares, competitors with a tourette syndrome treatment market share, detailed tourette syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tourette syndrome treatment industry. This tourette syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tourette syndrome treatment involves managing the symptoms of Tourette syndrome, including tics and behavioral issues. It includes a variety of interventions, such as medications, behavioral therapies, and supportive services, aimed at reducing the frequency and severity of symptoms and enhancing the overall quality of life for individuals with Tourette syndrome.

The primary drug classes used in Tourette syndrome treatment include antiadrenergic agents, antipsychotic agents, atypical antipsychotic agents, carbonic anhydrase inhibitors, anticonvulsants, and others. Antiadrenergic agents are medications that block or reduce the effects of adrenaline and noradrenaline. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used in both pediatric and adult patients.

The tourette syndrome treatment market consists of revenues earned by entities by providing services, such as pharmacotherapy, behavioral therapies, neurostimulation techniques, and supportive services used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The Tourette syndrome treatment market also includes sales of antipsychotics, wrist devices, and non-antipsychotic medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.